CZ302750B6 - Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku - Google Patents

Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku Download PDF

Info

Publication number
CZ302750B6
CZ302750B6 CZ20020264A CZ2002264A CZ302750B6 CZ 302750 B6 CZ302750 B6 CZ 302750B6 CZ 20020264 A CZ20020264 A CZ 20020264A CZ 2002264 A CZ2002264 A CZ 2002264A CZ 302750 B6 CZ302750 B6 CZ 302750B6
Authority
CZ
Czechia
Prior art keywords
concentration
benzethonium chloride
composition
phenoxyethanol
solution
Prior art date
Application number
CZ20020264A
Other languages
Czech (cs)
English (en)
Other versions
CZ2002264A3 (cs
Inventor
Gayed@Atef
Original Assignee
Aventis Holdings Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Holdings Inc. filed Critical Aventis Holdings Inc.
Publication of CZ2002264A3 publication Critical patent/CZ2002264A3/cs
Publication of CZ302750B6 publication Critical patent/CZ302750B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CZ20020264A 1999-07-22 2000-07-21 Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku CZ302750B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19821699P 1999-07-22 1999-07-22

Publications (2)

Publication Number Publication Date
CZ2002264A3 CZ2002264A3 (cs) 2002-06-12
CZ302750B6 true CZ302750B6 (cs) 2011-10-19

Family

ID=22732468

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20020264A CZ302750B6 (cs) 1999-07-22 2000-07-21 Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku

Country Status (25)

Country Link
US (1) US7432360B2 (cg-RX-API-DMAC10.html)
EP (1) EP1200115B9 (cg-RX-API-DMAC10.html)
JP (1) JP2003517462A (cg-RX-API-DMAC10.html)
KR (1) KR100693263B1 (cg-RX-API-DMAC10.html)
CN (2) CN101091792A (cg-RX-API-DMAC10.html)
AT (1) ATE304863T1 (cg-RX-API-DMAC10.html)
AU (1) AU777397B2 (cg-RX-API-DMAC10.html)
BR (1) BR0012667A (cg-RX-API-DMAC10.html)
CA (1) CA2378945C (cg-RX-API-DMAC10.html)
CZ (1) CZ302750B6 (cg-RX-API-DMAC10.html)
DE (1) DE60022759T2 (cg-RX-API-DMAC10.html)
DK (1) DK1200115T3 (cg-RX-API-DMAC10.html)
EA (1) EA006220B1 (cg-RX-API-DMAC10.html)
EE (1) EE200200037A (cg-RX-API-DMAC10.html)
ES (1) ES2248110T3 (cg-RX-API-DMAC10.html)
HK (1) HK1050318A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20020159B1 (cg-RX-API-DMAC10.html)
HU (1) HUP0202246A3 (cg-RX-API-DMAC10.html)
IL (2) IL147755A0 (cg-RX-API-DMAC10.html)
NO (1) NO20020303L (cg-RX-API-DMAC10.html)
NZ (1) NZ516735A (cg-RX-API-DMAC10.html)
PL (1) PL202945B1 (cg-RX-API-DMAC10.html)
RS (1) RS50355B (cg-RX-API-DMAC10.html)
WO (1) WO2001007075A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200200742B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147756A (en) 1999-07-22 2005-12-18 Aventis Pharma Inc Preserved pharmaceutical formulations
MEP90708A (hr) 2000-05-15 2011-12-20 Nova farmaceutska smješa
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CN1960745A (zh) * 2004-03-26 2007-05-09 詹森药业有限公司 促红细胞生成素组合加药方案
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
EP1845934B1 (de) * 2005-02-03 2008-05-14 Clariant Produkte (Deutschland) GmbH Konservierungsmittel
JP2011116752A (ja) * 2009-10-29 2011-06-16 Jcr Pharmaceuticals Co Ltd エリスロポエチン含有水性液剤
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
ES2982752T3 (es) * 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199992A1 (en) * 1985-03-28 1986-11-05 Eisai Co., Ltd. Adsorption-resistant peptide composition and use of benzalkonium or benzethonium chloride in the preparation thereof
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
EP0459795A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
US5503827A (en) * 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP2532025B2 (ja) * 1993-07-23 1996-09-11 株式会社林原生物化学研究所 新リンホカインiiiを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
WO1995033474A1 (en) * 1994-06-03 1995-12-14 Tsumura & Co. Medicinal composition
JP2000504319A (ja) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JPH1112193A (ja) * 1997-06-19 1999-01-19 Sankyo Co Ltd ヒトカルシトニン含有水溶液製剤
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199992A1 (en) * 1985-03-28 1986-11-05 Eisai Co., Ltd. Adsorption-resistant peptide composition and use of benzalkonium or benzethonium chloride in the preparation thereof
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
EP0459795A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
US5503827A (en) * 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Durieux et al.: Synergistic inhibition of muscarinic signalling by ketamine stereoisomer and preservative benzethonium chloride, ANESTHESIOLOGY. 1997, vol. 86 c. 6, str. 1326-1333, abstrakt *

Also Published As

Publication number Publication date
CA2378945C (en) 2010-02-23
NO20020303D0 (no) 2002-01-21
HRP20020159B1 (en) 2007-08-31
BR0012667A (pt) 2002-07-02
WO2001007075A3 (en) 2001-10-04
AU777397B2 (en) 2004-10-14
CA2378945A1 (en) 2001-02-01
DE60022759D1 (de) 2006-02-02
EP1200115B1 (en) 2005-09-21
NO20020303L (no) 2002-03-21
ATE304863T1 (de) 2005-10-15
IL147755A0 (en) 2002-08-14
AU7137400A (en) 2001-02-13
KR100693263B1 (ko) 2007-03-13
CZ2002264A3 (cs) 2002-06-12
EP1200115A2 (en) 2002-05-02
DE60022759T2 (de) 2006-06-22
HRP20020159A2 (en) 2003-06-30
PL353569A1 (en) 2003-12-01
EE200200037A (et) 2003-04-15
EA200200073A1 (ru) 2002-08-29
US20050267033A1 (en) 2005-12-01
RS50355B (sr) 2009-11-10
HK1050318A1 (zh) 2003-06-20
JP2003517462A (ja) 2003-05-27
YU4702A (sh) 2005-06-10
EP1200115B9 (en) 2006-01-18
HUP0202246A2 (en) 2002-10-28
CN101091792A (zh) 2007-12-26
ES2248110T3 (es) 2006-03-16
EA006220B1 (ru) 2005-10-27
DK1200115T3 (da) 2006-01-16
CN1371284A (zh) 2002-09-25
US7432360B2 (en) 2008-10-07
ZA200200742B (en) 2003-06-25
KR20020011143A (ko) 2002-02-07
PL202945B1 (pl) 2009-08-31
NZ516735A (en) 2004-01-30
HUP0202246A3 (en) 2010-01-28
IL147755A (en) 2009-11-18
WO2001007075A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
CA2139358C (en) Human growth hormone aqueous formulation
AU2003213142A1 (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
AU2004237982A1 (en) Liquid stabilized protein formulations in coated pharmaceutical containers
IE64080B1 (en) Pharmaceutical for subcutaneous administration containing polypeptides
RU2242242C2 (ru) Препаративная форма стабильного водного раствора интерферона, способ ее приготовления и использования
WO2023211501A1 (en) Stable, ready-to-administer aqueous formulations of dalbavancin
US20220160816A1 (en) Angiotensin compositions and methods related thereto
CA2378945C (en) Multi-dose erythropoietin formulations
KR100271671B1 (ko) 고농도 tcf 주사제
AU2004244920A1 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
JP3100058B2 (ja) 線維芽細胞成長因子を含む安定な医薬組成物
EP0345926A1 (en) Pharmaceutical compositions containing pentamidine
SK286990B6 (sk) Viacdávková kompozícia na báze erytropoetínu
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
MXPA02000804A (en) Multi dose erythropoietin formulations
WO2025235305A1 (en) Azithromycin premix formulation and product, methods of preparing same, and methods of using same
HK1116419A (en) Multi-dose erythropoietin formulations
Chaubal et al. Drug Delivery: Parenteral Route

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20120721